Oncostatin M is a signaling molecule produced by immune cells that influences an unusually wide range of tissues, from the liver and bone marrow to the gut, brain, joints, and skin. It belongs to the interleukin-6 (IL-6) family of cytokines, a group of small proteins that immune cells release to coordinate inflammation and tissue repair. What makes oncostatin M stand out, even among that versatile family, is how context-dependent its effects are: in some settings it promotes healing and normal development, while in others it drives chronic inflammation, fibrosis, or tumor progression. Researchers across a dozen medical specialties are studying it, and clinical trials are already testing drugs that block it.
Where Oncostatin M Comes From
Oncostatin M is produced relatively late in the immune response, primarily by activated T cells and macrophages.1The Journal of Immunology. Regulation of Inflammatory Responses by Oncostatin M That timing matters. Early-response cytokines tend to sound the alarm and recruit immune cells to a site of injury or infection. Oncostatin M arrives after the initial wave and helps shape what happens next: whether inflammation resolves, whether tissue gets repaired, or whether the immune response spirals into something damaging. Macrophages in fat tissue also produce it, and levels climb in obesity and type 2 diabetes.2PubMed Central. Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes In the skin, dermal T cells and monocytes are the main sources.3PubMed Central. Oncostatin M can sensitize sensory neurons in inflammatory pruritus The picture that emerges is of a cytokine that immune cells release wherever they congregate in inflamed tissue, and its downstream effects depend heavily on which cell types are nearby to receive the signal.
How It Signals and Why Species Differences Matter
Oncostatin M works by binding to receptor complexes on the surface of target cells. In humans, there are two receptor types it can use. Both include gp130, a shared receptor subunit that several IL-6 family cytokines also use. The first type pairs gp130 with the LIF receptor subunit, the same receptor used by a closely related cytokine called leukemia inhibitory factor (LIF). The second type pairs gp130 with a subunit called OSM receptor beta, or OSMRβ, which is specific to oncostatin M.4Blood. Reconstitution of the Functional Mouse Oncostatin M (OSM) Receptor: Molecular Cloning of the Mouse OSM Receptor β Subunit This dual-receptor arrangement explains some of the overlap between oncostatin M and LIF: when oncostatin M binds the shared receptor, it can mimic LIF’s effects, while the OSMRβ-specific receptor drives activities unique to oncostatin M.
There is a significant wrinkle for researchers. Mouse oncostatin M does not activate the shared LIF-type receptor at all; it only signals through the OSMRβ-specific pathway.5Blood. Reconstitution of the Functional Mouse Oncostatin M (OSM) Receptor: Molecular Cloning of the Mouse OSM Receptor β Subunit That means results from mouse experiments do not always translate cleanly to humans, since the human version of the cytokine has an entire additional receptor pathway available to it. Researchers have to account for this when interpreting animal data, and it has sometimes led to confusion about whether oncostatin M is protective or harmful in a given disease.
Normal Roles in Development and Tissue Maintenance
Despite all the attention paid to its role in disease, oncostatin M performs essential jobs in healthy development. One of its best-characterized normal functions is in the fetal liver. During embryonic development, the liver needs to mature from a blood-forming organ into the metabolic powerhouse it becomes after birth. Oncostatin M, acting through the gp130 receptor, drives that transition: it helps fetal liver cells take on the appearance and gene activity of mature hepatocytes, start storing glycogen, and generally behave like adult liver cells. Mice engineered to lack the gp130 receptor show clear defects in liver maturation, confirming that oncostatin M signaling is not optional for this process.6PubMed Central. Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer
Oncostatin M also helps maintain the bone marrow environment where blood stem cells live. It does this by keeping the balance between fat cells and bone-forming cells in the marrow tilted in favor of bone. Mice that lack oncostatin M develop increasingly fatty bone marrow as they age and show low blood cell counts across all lineages. When oncostatin M is given to irradiated mice after a bone marrow transplant, it blocks fatty marrow buildup and improves blood stem cell recovery.7PLoS ONE. Oncostatin M Maintains the Hematopoietic Microenvironment in the Bone Marrow by Modulating Adipogenesis and Osteogenesis Additionally, oncostatin M acts as a brake on blood stem cell mobilization: it holds stem cells in the marrow rather than letting them flood into the bloodstream. This matters clinically because mobilizing stem cells into the blood is a key step in stem cell transplantation. Blocking oncostatin M signaling enhances mobilization in mice that are normally poor mobilizers.8PubMed. Oncostatin M regulates hematopoietic stem cell niches in the bone marrow to restrict HSC mobilization
Gut Inflammation and Predicting Treatment Failure
One of the most clinically consequential findings about oncostatin M involves inflammatory bowel disease (IBD). A landmark study published in Nature Medicine showed that oncostatin M drives intestinal inflammation and, more practically, predicts whether patients will respond to anti-TNF therapy, the most widely used class of biologic drugs for Crohn’s disease and ulcerative colitis. In an analysis of over 200 IBD patients from two phase 3 clinical trials of infliximab and golimumab, high oncostatin M levels before treatment began were strongly associated with failure of those anti-TNF drugs.9PubMed Central. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease That finding matters because anti-TNF therapy fails in a substantial fraction of IBD patients, and clinicians currently lack reliable ways to know in advance who will benefit. Oncostatin M levels could help spare non-responders months of ineffective treatment.
More recent work has reinforced oncostatin M’s value as a biomarker in ulcerative colitis specifically. Serum levels correlate with both endoscopic and histological disease severity: patients with inflammation throughout the entire colon have higher levels than those with disease limited to the left side. In one study, serum oncostatin M outperformed fecal calprotectin, the current go-to stool biomarker, in detecting histologically active disease, with an area under the curve of 0.967 versus 0.875.10Journal of Crohn’s and Colitis. P0630 Serum Oncostatin M Levels in Ulcerative Colitis – Correlation with Endoscopic and Histological Disease Severity A blood test is easier to repeat than a colonoscopy or stool sample, so if oncostatin M proves reliable across larger studies, it could change how disease activity is monitored.
Joint Disease and the Inflammatory Subset
Oncostatin M is consistently elevated in the joint fluid of people with rheumatoid arthritis, but its role in osteoarthritis is more selective. A study comparing inflammatory and mechanical models of arthritis in animals found that oncostatin M expression tracked with synovial inflammation and bony spur formation in the inflammatory model but was absent in the purely mechanical (joint instability) model, even though both produced cartilage damage.11PubMed Central. Association between Oncostatin M Expression and Inflammatory Phenotype in Experimental Arthritis Models and Osteoarthritis Patients When researchers looked at human osteoarthritis patients, only a subset had detectable oncostatin M in their synovial fluid, and those patients also had higher levels of other inflammatory cytokines like interferon gamma, IL-1α, and TNF-α.12PubMed Central. Association between Oncostatin M Expression and Inflammatory Phenotype in Experimental Arthritis Models and Osteoarthritis Patients The implication is that oncostatin M marks a specific inflammatory subset of osteoarthritis patients, not the disease as a whole, which could eventually help target treatments toward the patients most likely to benefit from anti-inflammatory approaches.
The Brain and Blood-Brain Barrier
Oncostatin M has a disruptive effect on the blood-brain barrier, the tightly sealed layer of cells that normally prevents immune molecules and cells from entering brain tissue. Research shows that oncostatin M weakens this barrier by reducing two key structural proteins, claudin-5 and VE-cadherin, in the cells lining brain blood vessels. At the same time, it triggers those cells and nearby astrocytes to secrete a chemical signal called CCL20 that attracts a pro-inflammatory type of immune cell (Th17 cells) into the brain.13PubMed. Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity The result is a two-hit problem: the barrier opens, and inflammatory cells are actively recruited through the gap.
A recent study in stroke models extended this story. After a blocked brain artery is reopened (so-called ischemia-reperfusion injury), microglia in the brain ramp up oncostatin M production, and astrocytes increase their display of the OSM receptor. When researchers knocked out either the receptor on astrocytes or oncostatin M production in microglia, the blood-brain barrier stayed more intact, stroke damage was smaller, and neurological function improved.14PubMed. Targeting the Microglia-Astrocyte OSM-OSMR Axis Restores Blood-Brain Barrier Integrity After Experimental Cerebral Ischemia-Reperfusion in Mice These are animal findings for now, but they point toward oncostatin M as a potential therapeutic target in stroke and neuroinflammatory diseases like multiple sclerosis.
Cancer, Stem Cell Traits, and Treatment Resistance
In cancer biology, oncostatin M draws attention because it can push tumor cells into more aggressive states. In pancreatic cancer, oncostatin M drives cells to undergo an identity shift toward both a mesenchymal phenotype (cells that are more mobile and invasive) and a cancer stem cell phenotype (cells that are better at seeding new tumors and resisting chemotherapy). Pancreatic cancer cells exposed to oncostatin M showed enhanced ability to form tumors, increased metastasis, and resistance to gemcitabine, a standard chemotherapy drug for that cancer.15PubMed Central. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer
Mechanistically, oncostatin M activates the JAK-STAT3 signaling pathway in tumor cells and switches on transcription factors that orchestrate the mesenchymal shift. It also induces production of its own receptor, creating a feedback loop that amplifies the signal. In laboratory experiments, the JAK1/2 inhibitor ruxolitinib blocked this entire cascade, preventing the emergence of aggressive cell traits.16PubMed Central. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer Since ruxolitinib is already approved for other conditions, this raises the question of whether it or similar drugs might eventually be tested as combination therapy in pancreatic cancer to prevent treatment resistance.
Heart Disease and a Possible Screening Biomarker
Blood levels of oncostatin M are higher in people with coronary artery disease, and the degree of elevation tracks with disease severity. In a study of over 300 patients who underwent coronary angiography, those with significant artery blockages had average serum oncostatin M levels around 123 pg/mL, compared with about 98 pg/mL in patients without blockages. Patients with the most complex and severe lesions had even higher levels, averaging around 140 pg/mL. After patients with single-vessel disease underwent stent placement, their oncostatin M levels dropped significantly.17PubMed Central. Oncostatin M is a novel biomarker for coronary artery disease – A possibility as a screening tool of silent myocardial ischemia for diabetes mellitus The authors proposed oncostatin M as a potential screening tool for silent heart disease in people with diabetes, who often develop coronary blockages without typical chest pain symptoms. Whether it is specific enough to be useful in clinical screening still needs larger validation studies.
Metabolic Health and Fat Tissue Inflammation
The connection between oncostatin M and obesity is a case study in how immune cells and fat cells talk to each other. In both rodents and humans, oncostatin M levels in fat tissue rise with weight gain and insulin resistance. In humans, levels correlate with body weight and circulating insulin, and they are inversely correlated with how efficiently the body disposes of glucose. The source of the cytokine is not the fat cells themselves but the immune cells embedded in fat tissue, particularly macrophages.18PubMed Central. Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes When macrophages in fat tissue release oncostatin M, it acts on neighboring fat cells to promote a pro-inflammatory state. This paracrine loop helps explain why obesity is associated with chronic low-grade inflammation: the more fat tissue accumulates, the more macrophages infiltrate it, the more oncostatin M they produce, and the more inflamed the tissue becomes.
Skin Itch Without Directly Activating Nerves
Chronic itch is one of the most disabling symptoms in inflammatory skin diseases like psoriasis, atopic dermatitis, and cutaneous T cell lymphoma. Oncostatin M is highly elevated in all three conditions, and research has uncovered a surprising mechanism for how it contributes to itch. Unlike classical itch-triggering molecules, oncostatin M does not directly activate sensory neurons. Instead, it sensitizes them. It lowers the threshold at which neurons fire in response to other itch-causing signals and increases their overall excitability.19PubMed Central. Oncostatin M can sensitize sensory neurons in inflammatory pruritus The OSM receptor sits on a specific population of itch-sensing neurons. When mice had this receptor knocked out on their sensory neurons, both oncostatin M-driven itch and broader inflammatory itch were reduced. Blocking the receptor with a drug also relieved itch in a mouse model of inflammatory dermatitis. This sensitization mechanism is an appealing drug target precisely because it is upstream of many different itch triggers: rather than blocking one pruritogen at a time, blocking the sensitizer could dampen itch more broadly.
Lung Fibrosis and Wound Repair
Oncostatin M stimulates lung fibroblasts to proliferate, produce collagen, and resist programmed cell death. In laboratory experiments, it increased collagen production by about 35% over baseline levels in human lung fibroblasts.20PubMed Central. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts These are exactly the activities that, when properly controlled, heal a wound, but when dysregulated, produce fibrotic scarring. This dual nature is a recurring theme with oncostatin M: the same pro-repair signals that restore tissue after an injury can, if they persist, lead to pathological fibrosis. In the lungs, this has implications for conditions like idiopathic pulmonary fibrosis and fibrotic complications after severe infections.
Sepsis and the Potential as a Prognostic Marker
In critically ill patients with sepsis, oncostatin M levels spike in the blood within the first day of ICU admission and then gradually decline. Patients who die within 28 days have significantly higher levels on admission than those who survive. In one study, oncostatin M outperformed both the SOFA organ failure score and procalcitonin (a widely used sepsis marker) at predicting 28-day mortality, with an area under the ROC curve of 0.80 compared with 0.73 for SOFA and 0.65 for procalcitonin.21The Journal of Infectious Diseases. Oncostatin M Is a Prognostic Biomarker and Inflammatory Mediator for Sepsis Combined with the SOFA score, oncostatin M was an independent predictor of death. This does not mean it is ready for routine clinical use, but it adds to the growing list of settings where oncostatin M levels carry clinically meaningful information.
Pregnancy and Placental Implantation
For a pregnancy to succeed, trophoblast cells from the developing embryo must invade the uterine wall deeply enough to establish a blood supply. Oncostatin M appears to help this process. In laboratory studies using first-trimester trophoblast cells, oncostatin M increased invasion in both a time-dependent and dose-dependent manner, partly by boosting the activity of matrix metalloproteinase-2, an enzyme that breaks down the structural proteins in tissue.22PubMed. The effects of oncostatin M on trophoblast cells: influence on matrix metalloproteinases-2 and -9, and invasion activity Under low-oxygen conditions, which mimic the early uterine environment, the invasion-promoting effect was more pronounced.23Yonsei Medical Journal. Effects of Oncostatin M on Invasion of Primary Trophoblasts under Normoxia and Hypoxia Conditions The signaling pathways involved include STAT3 and ERK, and blocking either one reduced trophoblast invasion.24Yonsei Medical Journal. STAT3 and ERK Signaling Pathways Are Implicated in the Invasion Activity by Oncostatin M through Induction of Matrix Metalloproteinases 2 and 9 How these findings relate to pregnancy complications like pre-eclampsia, where trophoblast invasion is often shallow, is an active area of investigation.
Lung Infections and the Protective Side
Not everything oncostatin M does is harmful. In the lungs, it plays a protective role during respiratory infections. A preprint study found that loss of oncostatin M shifted lung macrophages toward an excessively inflammatory phenotype during influenza infection and worsened lung injury during bacterial pneumonia.25bioRxiv. Non-canonical Oncostatin M Signaling Provides Protection during Respiratory Viral and Bacterial infections In other words, oncostatin M was helping to prevent the immune system from overshooting and damaging the lung tissue it was supposed to defend. This is a reminder that oncostatin M is not simply a “bad” inflammatory signal. In the right context and at the right dose, it restrains inflammation rather than amplifying it. That duality complicates drug development: blocking oncostatin M systemically might help in autoimmune disease but could leave patients more vulnerable to infection-related lung damage.
Therapeutic Targeting
Given oncostatin M’s involvement in so many inflammatory and fibrotic conditions, pharmaceutical companies have begun developing drugs that block it. GSK2330811 is a monoclonal antibody against oncostatin M that has been tested in a phase 2 trial for systemic sclerosis, a disease in which skin and internal organs become progressively scarred.26PubMed Central. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis The rationale is straightforward: if oncostatin M promotes fibroblast proliferation, collagen deposition, and inflammation in skin and lung tissue, blocking it might slow or halt the scarring process. Early-phase trials like this one are primarily testing safety and biological activity rather than long-term efficacy, so it remains early days. Other potential applications, including IBD patients who fail anti-TNF therapy and inflammatory skin conditions, are being explored preclinically. The JAK inhibitor ruxolitinib, which blocks signaling downstream of the oncostatin M receptor, is another angle being studied in cancer settings. Whether any of these approaches will reach widespread clinical use depends on navigating the same duality that defines oncostatin M itself: blocking it where it causes harm without disrupting its protective and developmental roles elsewhere.